Lluch A - Search Results

1

MicroRNAs in Breast Cancer: One More Turn in Regulation.

Eroles P, Tormo E, Pineda B, Espin E, Lluch A. Eroles P, et al. Among authors: lluch a. Curr Drug Targets. 2016;17(9):1083-100. doi: 10.2174/1389450116666150213114103. Curr Drug Targets. 2016. PMID: 25694121 Review.

2

Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Bosch A, et al. Among authors: lluch a. Cancer Treat Rev. 2010 May;36(3):206-15. doi: 10.1016/j.ctrv.2009.12.002. Epub 2010 Jan 8. Cancer Treat Rev. 2010. PMID: 20060649 Review.

3

Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Eroles P, et al. Among authors: lluch a. Cancer Treat Rev. 2012 Oct;38(6):698-707. doi: 10.1016/j.ctrv.2011.11.005. Epub 2011 Dec 16. Cancer Treat Rev. 2012. PMID: 22178455 Review.

4

The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. Rodrigues P, et al. Among authors: lluch a. Breast Cancer Res Treat. 2012 Jun;133(2):769-78. doi: 10.1007/s10549-012-1980-1. Breast Cancer Res Treat. 2012. PMID: 22315135

5

Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.

Pineda B, García-Pérez MÁ, Cano A, Lluch A, Eroles P. Pineda B, et al. Among authors: lluch a. PLoS One. 2013;8(1):e53902. doi: 10.1371/journal.pone.0053902. Epub 2013 Jan 16. PLoS One. 2013. PMID: 23342035 Free PMC article.

6

Identification of candidate polymorphisms on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients.

Rodrigues P, Furriol J, Bermejo B, Chaves FJ, Lluch A, Eroles P. Rodrigues P, et al. Among authors: lluch a. Int J Mol Sci. 2012 Dec 5;13(12):16500-13. doi: 10.3390/ijms131216500. Int J Mol Sci. 2012. PMID: 23443115 Free PMC article. Clinical Trial.

7

Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. Rodrigues P, et al. Among authors: lluch a. Mol Cell Biochem. 2013 Jul;379(1-2):181-90. doi: 10.1007/s11010-013-1640-8. Epub 2013 Apr 6. Mol Cell Biochem. 2013. PMID: 23716179

8

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.

Pérez-Fidalgo JA, Eroles P, Ferrer J, Bosch A, Burgués O, Martínez F, Bermejo B, Lluch A, González-Angulo AM. Pérez-Fidalgo JA, et al. Among authors: lluch a. Breast. 2013 Oct;22(5):974-9. doi: 10.1016/j.breast.2013.05.014. Epub 2013 Jun 25. Breast. 2013. PMID: 23809906

9

Concordance of genomic alterations between primary and recurrent breast cancer.

Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Meric-Bernstam F, et al. Among authors: lluch am. Mol Cancer Ther. 2014 May;13(5):1382-9. doi: 10.1158/1535-7163.MCT-13-0482. Epub 2014 Mar 7. Mol Cancer Ther. 2014. PMID: 24608573 Free PMC article.

10

Emerging EGFR antagonists for breast cancer.

Lluch A, Eroles P, Perez-Fidalgo JA. Lluch A, et al. Expert Opin Emerg Drugs. 2014 Jun;19(2):165-81. doi: 10.1517/14728214.2014.903919. Epub 2014 May 15. Expert Opin Emerg Drugs. 2014. PMID: 24831079 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

426 results

Search Page